AI Article Synopsis
- The "innate-like" T cell compartment, referred to as T, consists of diverse T cells that bridge innate and adaptive immunity and is analyzed using advanced techniques like single-cell RNA sequencing.
- In human blood, most T cells exhibit an effector program driven by unique transcription factors, contrasting with conventional T cells, while varied developmental stages are observed in thymic T cells.
- Unlike mice, human T cells do not form multiple effector subsets but show a mix of type 1 and type 17 effector potential, revealing key differences in immune regulation between species.
Article Abstract
The "innate-like" T cell compartment, known as T, represents a diverse group of T cells that straddle the boundary between innate and adaptive immunity. We explore the transcriptional landscape of T compared to conventional T cells (T) in the human thymus and blood using single-cell RNA sequencing (scRNA-seq) and flow cytometry. In human blood, the majority of T cells share an effector program driven by specific transcription factors, distinct from those governing T cells. Conversely, only a fraction of thymic T cells displays an effector phenotype, while others share transcriptional features with developing T cells, indicating potential divergent developmental pathways. Unlike the mouse, human T cells do not differentiate into multiple effector subsets but develop a mixed type 1/type 17 effector potential. Cross-species analysis uncovers species-specific distinctions, including the absence of type 2 T cells in humans, which implies distinct immune regulatory mechanisms across species.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552652 | PMC |
| http://dx.doi.org/10.1016/j.celrep.2024.114705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy.
Expert Opin Biol Ther
December 2024
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy and have enhanced the survival of patients with malignant tumors. However, the overall efficacy of ICIs remains unsatisfactory and is faced with two major concerns of resistance development and occurrence of immune-related adverse events (irAEs). Bispecific antibodies (bsAbs) have emerged as promising strategies with unique mechanisms of action to achieve a better efficacy and safety than monoclonal antibodies (mAbs) or even their combination.
View Article and Find Full Text PDFCurrent status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy.
Int Immunopharmacol
December 2024
Department of Life Sciences, University of Science and Technology of Hanoi (USTH), Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam. Electronic address:
Article Synopsis
- Immunogenic cell death (ICD) is a process that includes various forms of cell death like apoptosis and necroptosis, which helps stimulate an immune response against cancer cells by utilizing damage signals and tumor-associated antigens.
- ICD is a promising strategy in cancer immunotherapy because it can both directly kill cancer cells and promote long-lasting immune reactions against tumors, and traditional therapies like radiation and chemotherapy can also induce ICD to enhance their effectiveness.
- The use of nanoparticles in cancer therapy is highlighted as a key development for inducing ICD safely and effectively, as they improve the delivery of treatment, target cancer sites better, and reduce side effects compared to conventional therapies.
Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy.
Nat Commun
October 2023
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning, 110016, P. R. China.
Cytokine therapy, involving interleukin-15 (IL-15), is a promising strategy for cancer immunotherapy. However, clinical application has been limited due to severe toxicity and the relatively low immune response rate, caused by wide distribution of cytokine receptors, systemic immune activation and short half-life of IL-15. Here we show that a biomimetic nanovaccine, developed to co-deliver IL-15 and an antigen/major histocompatibility complex (MHC) selectively targets IL-15 to antigen-specific cytotoxic T lymphocytes (CTL), thereby reducing off-target toxicity.
View Article and Find Full Text PDFCanvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.
Vaccines (Basel)
November 2022
Protein Biochemistry Research Centre, Dr. D. Y. Patil Biotechnology & Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Tathawade, Pune 411033, Maharashtra, India.
In view of the severe downsides of conventional cancer therapies, the quest of developing alternative strategies still remains of critical importance. In this regard, antigen cross-presentation, usually employed by dendritic cells (DCs), has been recognized as a potential solution to overcome the present impasse in anti-cancer therapeutic strategies. It has been established that an elevated cytotoxic T lymphocyte (CTL) response against cancer cells can be achieved by targeting receptors expressed on DCs with specific ligands.
View Article and Find Full Text PDFShortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells.
Biomolecules
September 2022
Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.
Article Synopsis
- T cell engager (TCE) antibodies are innovative cancer treatments that connect T-cells to tumor cells by binding to both T-cell receptors (CD3E) and tumor markers (TAA).
- The study focuses on a bispecific antibody format (IgG-like Fab x sdAb-Fc) that targets mEGFR on tumors and mCD3E on T-cells, analyzing the effect of hinge design in the sdAb.
- The findings reveal that a shorter hinge (23 amino acids) enhances tumor cell elimination and T-cell activation compared to a longer hinge (39 amino acids), suggesting that small design modifications can significantly boost the effectiveness of these therapeutic antibodies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!